1.	Phase III/IV Randomized Study of Risk-Adapted Therapy Comprising Observation Only, Combination Chemotherapy, Radiotherapy, and/or Autologous Stem Cell Transplantation in Younger Patients With Neuroblastoma Phase: Phase IV, Phase III Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: GPOH-NB2004, EU-20661, NCT00410631
2.	Phase III Randomized Study of Adjuvant Isotretinoin With or Without Monoclonal Antibody Ch14.18, Interleukin-2, and Sargramostim (GM-CSF) in Patients With Neuroblastoma Who Have Completed Myeloablative Therapy and Autologous Stem Cell Transplantation (Arm I Closed to Accrual as of 4/16/2009) Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 30 and under at diagnosis Sponsor: NCI Protocol IDs: COG-ANBL0032, ANBL0032, COG-P9842, NCT00026312
3.	Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 to 20 at diagnosis Sponsor: Other Protocol IDs: CDR0000069191, SIOP-EUROPE-HR-NBL-1, ESIOP, EU-20148, NCT00030719
4.	Phase III Randomized Study of Standard Chemoradiotherapy With or Without Carboplatin Followed by Standard Maintenance Therapy With or Without Isotretinoin and Continuation Therapy With Isotretinoin Versus No Continuation Therapy in Pediatric Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor Phase: Phase III Type: Treatment Status: Active Age: 3 to 21 Sponsor: NCI Protocol IDs: COG-ACNS0332, ACNS0332, NCT00392327
5.	Phase I/II Study of Vorinostat (SAHA) in Combination With Isotretinoin in Patients With Advanced Renal Cell Carcinoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 21 and over Sponsor: NCI Protocol IDs: NYWCCC-0511008257, 6896, NCI-6896, NCT00324740
6.	Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM) Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2006-0709, NCT00555399
7.	ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 8 and under Sponsor: Pharmaceutical / Industry Protocol IDs: DIV-NB-201, NCT01592045
8.	Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors Phase: Phase II Type: Treatment Status: Active Age: 6 months to 21 years Sponsor: Other Protocol IDs: NYU 05-40 H12853, PBMTC ONC-032P, NCT00528437
9.	Phase II Study of Protracted Oral Etoposide and Cisplatin During Induction Therapy in Pediatric Patients With Previously Untreated High-Risk Neuroblastoma Undergoing High-Dose Chemotherapy and Stem Cell Rescue Followed by Maintenance Therapy Comprising Isotretinoin Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Under 18 Sponsor: Other Protocol IDs: BCM-H-20225, 20255, NCT00600132
10.	High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 months and over Sponsor: Other Protocol IDs: 09-158, NCT01183416
11.	High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 months and over Sponsor: Other Protocol IDs: 09-159, NCT01183429
12.	High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma Phase: Phase II Type: Treatment Status: Active Age: 18 months and over Sponsor: Other Protocol IDs: 09-160, NCT01183884
13.	High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow Phase: Phase II Type: Treatment Status: Active Age: 18 months and over Sponsor: Other Protocol IDs: 09-161, NCT01183897
14.	PXD101 and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000479715, U01CA062505, CCC-PHI-53, NCI-7251, 7251, NCT00334789
15.	Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CCCWFU 91209, NCI-2010-00132, NCT01103375
16.	Phase I Study of Vorinostat in Combination With Isotretinoin in Patients With High-Risk Refractory or Recurrent Neuroblastoma Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 30 and under Sponsor: NCI Protocol IDs: NANT-N2008-02, N2008-02, NCT01208454
17.	Aflac ST1001 Prolonged Isotretinoin Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 30 and under Sponsor: Other Protocol IDs: Aflac ST1001, NCT01319838
18.	Randomized Study of Standard Induction Chemotherapy Versus Topotecan Hydrochloride-Containing Induction Chemotherapy Followed by Myeloablative Autologous Stem Cell Transplantation and Consolidation Therapy With Isotretinoin in Pediatric Patients With High-Risk Neuroblastoma Phase: No phase specified Type: Treatment Status: Active Age: 6 months to 21 Sponsor: Other Protocol IDs: GPOH-NB2004-HR, NB2004-HR, UNI-KOELN-161, NCT00526318, EU-20661
19.	Vorinostat, Isotretinoin, and Combination Chemotherapy in Treating Young Patients Who Have Undergone Surgery for Embryonal Tumors of the Central Nervous System Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 2 months to 3 years Sponsor: NCI, Other Protocol IDs: CDR0000636148, U01CA081457, PBTC-026, NCT00867178
20.	Pilot Study of Individualized Dosing of Isotretinoin in Pediatric Patients With High-Risk Neuroblastoma Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and under Sponsor: Other Protocol IDs: CCLG-PK-2008-03, PK 2008 03, EU-20914, EUDRACT-2008-003606-33, NCT00939965
21.	Pilot Study of Dose-Intensive Induction Therapy Including Iobenguane I 131 Followed by Consolidation Therapy Comprising Busulfan and Melphalan in Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Autologous Stem Cell Rescue, Radiotherapy, and Maintenance Therapy Comprising Isotretinoin Phase: No phase specified Type: Biomarker/Laboratory analysis, Health services research, Treatment Status: Active Age: 1 to 30 Sponsor: NCI Protocol IDs: COG-ANBL09P1, ANBL09P1, NCT01175356
22.	High Dose Chemotherapy and Autologous Transplant for Neuroblastoma Phase: No phase specified Type: Treatment Status: Active Age: 30 and under Sponsor: Other Protocol IDs: 2011OC072, MT2011-11C, NCT01526603